Fundraising Fox
/Companies
Sign in

ResQ Pharma

Glenview, US · United States corporation · 1 known investors

Find your way into ResQ Pharma

850 people in our graph share verified history with the ResQ Pharma team — schools, employers, funds. One of them is your warm intro.

John Cunninghamunlockedknows Mukesh Kumar · together at Akan Biosciences (overlapped)
knows the team · via Vivacelle Bio
×5knows the team · via National Institutes of Health
×5knows the team · via University of Illinois at Chicago

ResQ Pharma is a pharmaceutical company developing LipidRescue (LRT), an investigational lipid-based drug therapy that is pending FDA approval. The company works on biologics development, regulatory affairs, and clinical research for its drug candidate.

BiotechHealthtech

Founders & leadership

GWGuy Weinberg
Guy WeinbergDirector, President and Secretary of IssuerGuy Weinberg is a Professor of Anesthesiology at the University of Illinois Chicago who developed lipid rescue therapy for local anesthetic systemic toxicity, which became the standard of care worldwide, and is now president of ResQ Pharma, a company developing a standardized treatment kit for this condition pending FDA approval. He trained in internal medicine, medical genetics, and anesthesiology at UCSF, the NHLBI, and the University of Virginia, and maintained a basic science research laboratory for over 25 years.
DWDr. Weinberg
Dr. WeinbergFounder and PresidentDr. Weinberg is Professor of Anesthesiology at the University of Illinois Chicago with board certifications in internal medicine, medical genetics, and anesthesiology. He conducted research in mitochondrial mechanisms and developed lipid rescue therapy for local anesthetic systemic toxicity, which became standard of care in 2006, and now leads ResQ Pharma as it seeks FDA approval for a lipid-based drug therapy.
AH
August H. SchuppDirector, CAO and General Counsel of Issuer
DO
Dominic O'KeefeDirector and COO of Issuer
DB
David BowmanExecutive
DMDr. Mukesh Kumar
Dr. Mukesh KumarDirector of Regulatory AffairsDr. Mukesh Kumar held a staff scientist position at NIH focused on gene therapy research and later managed over 50 globally-sponsored clinical trials in regulatory affairs. He is now Director of Regulatory Affairs at ResQ Pharma, where he develops regulatory strategies for therapeutic products seeking US and EU approval.
MS
Mr. SchuppChief Administrative Officer and General Counsel
IR
Israel RubinsteinNamed on SEC filing

Board

PBPaul Burton
Paul BurtonBoard directorManaging Partner at 2Flo Ventures
JT
Joel TuneIndependent Director of Issuer
PH
Paul HertzBoard director
FW
Francis WisniewskiBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$2.4M disclosed across 5 rounds · 2015–2024

▶$100KraisedDec 2024 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • August H. SchuppExecutive Officer, Director, Promoter
  • Dominic O'KeefeExecutive Officer, Director, Promoter
  • Guy WeinbergExecutive Officer, Director, Promoter
  • Joel TuneExecutive Officer, Director, Promoter
Offering amount
$100K
Amount sold
$100K
First sale
Jul 2024
Incorporated
Corporation, United States
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$205.5KraisedJun 2022 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • August H. SchuppExecutive Officer, Director, Promoter
  • Joel TuneExecutive Officer, Director, Promoter
  • Dominic O'KeefeExecutive Officer, Director, Promoter
  • Guy WeinbergExecutive Officer, Director, Promoter
Offering amount
$300K
Amount sold
$205.5K
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedSep 2020 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Steve BylinaExecutive Officer, Director, Promoter
  • Francis WisniewskiExecutive Officer, Director, Promoter
  • August H. SchuppExecutive Officer, Director, Promoter
  • Guy WeinbergExecutive Officer, Director, Promoter
  • Antoinette GawinExecutive Officer, Director, Promoter
  • Todd BeckExecutive Officer, Director, Promoter
  • Paul HertzExecutive Officer, Director, Promoter
Offering amount
$2M
Amount sold
$1M
First sale
Jun 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$739.5KraisedSep 2016 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Francis WisniewskiDirector
  • Paul BurtonExecutive Officer, Director
  • Paul HertzDirector
  • Guy WeinbergDirector
  • Todd BeckExecutive Officer
  • Antoinette GawinDirector
Offering amount
$764.5K
Amount sold
$739.5K
Minimum investment
$9.6K
First sale
Aug 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$325KraisedMar 2016 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul HertzDirector
  • Paul BurtonExecutive Officer, Director
  • David BowmanExecutive Officer
  • Israel RubinsteinDirector
  • Francis WisniewskiDirector
  • Guy WeinbergDirector
Offering amount
$325K
Amount sold
$325K
Minimum investment
$5K
First sale
Sep 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
BioQ Pharma13 shared keywordsBioQ Pharma is a pharmaceutical company with expertise in biotech development and healthcare technology. The company appears to be focused on pharmaceutical innovation with a board of directors drawn from senior executives with extensive experience in biotech, medical devices, and pharma commercialization.
STAQ Pharma12 shared keywordsSTAQ Pharma is an FDA-registered 503B outsourcing facility that compounds and supplies medications to hospitals and healthcare providers across the United States, aiming to address drug shortages. The company is owned and guided by several healthcare systems and focuses on safety, transparency, availability, and quality.
SuppCo7 shared keywordsSupp.co is a platform for building, optimizing, and tracking personalized supplement stacks aligned with individual health goals and lifestyles. The company serves health-conscious consumers and biohackers seeking transparency and structure in supplement selection.

Companies competing with ResQ Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does ResQ Pharma do?
ResQ Pharma is a pharmaceutical company developing LipidRescue (LRT), an investigational lipid-based drug therapy that is pending FDA approval. The company works on biologics development, regulatory affairs, and clinical research for its drug candidate.
Who founded ResQ Pharma?
ResQ Pharma was founded by Guy Weinberg, Dr. Weinberg.
Who are ResQ Pharma's investors?
ResQ Pharma's investors include 2Flo Ventures.
How much funding has ResQ Pharma raised?
ResQ Pharma has disclosed $2.4M raised across 5 rounds.
Where is ResQ Pharma headquartered?
ResQ Pharma is headquartered in Glenview, US.